Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

3 treatments under study, led by Hlamismatched Stemcell Microtransplantation

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Terminated1
Completed1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00559065Completed

A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in China

NCT02255162Phase 1Terminated

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

Showing all 2 trials

Research Network

Common Treatments

  • Hlamismatched Stemcell Microtransplantation1
  • Lenalidomide1
  • Cytarabine1

Active Sponsors

  • China for Disease Control (CDC)1
  • National Cancer Institute (NCI)1
  • Celgene Corporation1
  • Massachusetts General Hospital1

Top Investigators

Related Conditions

  • Acute Myelogenous Leukemia1
  • Acute Myeloid Leukemia Aml1
  • Lymphoma1
  • Acute Granulocytic Leukemia1
  • Acute Myelocytic Leukemia1

Activity Timeline